| Timo Veromaa
Born: 1960
Education: M.D., Ph.D., special competence in pharmaceutical medicine
Position at Biotie: President and CEO
Appointed as member of the Management Team: December 1998
Employment history: Biotie Therapies Corp., Vice President of R&D 1998–2005. President and CEO from 2005. Schering Oy, Medical Director 1996–1998. Collagen Corporation (California, USA), research and program manager 1994–1996. Stanford University (California, USA), Postdoc Fellow 1990–1993. University of Turku, scientist 1985–1990.
Key positions of trust: Finnish Bioindustries, Chairman of the Board. Chairman of the Steering Committee for HealthBIO, a national cluster program focusing on health applications of biotechnology and on business areas related to health.
Number of shares held in Biotie |
| Antero Kallio
Born: 1960
Education: M.D., Ph.D., special competence in pharmaceutical medicine, postgraduate certifi cate in pharmacovigilance
Position at Biotie: Chief Medical Offi cer
Appointed as member of the Management Team: June 2005
Employment history: Biotie Therapies Corp., Director of clinical research 1998–2005, Director of drug development since 2005. Leiras Oy, Head of drug safety 1995–1998, acting Medical Director 1996–1997. Farmos Group Ltd and Orion Corporation, project and research manager 1988–1995. Orion-Farmos, Inc. (California, USA), VP clinical research 1993–1994. University of Turku, Department of Pharmacology and Clinical Pharmacology, scientist 1986–1988.
Other major duties: None
Number of shares held in Biotie 31.12.2009: 43,900
Number of option rights 31.12.2009:
Option program: 2006: 347,580; 2009: 250,000
|
 | Thomas Kronbach
Born: 1952
Education: Ph.D., key expertise areas comprise chemistry, pharmacology, molecular biology and drug metabolism.
Position at Biotie: Chief Scientifi c Offi cer
Appointed as member of the Management Team: November 2008
Employment history: elbion NV, Chief Scientifi c Offi cer of elbion and co-founder 2002–2008. AWD, a company of the Degussa group, Head of research and development, 2000–2002. Goedecke-Parke-Davis (Freiburg, Germany), Head Drug Metabolism, 1990–1991. The Scripps Research Institute (La Jolla, California, USA), Research Associate, 1986–1990. Biocenter of the University of Basle, Switzerland, Post Doctoral Fellow, 1982–1986. University of Tuebingen, Germany, Ph.D in chemistry 1982.
Key positions of trust: None
Number of shares held in Biotie 31.12.2009:
– through his controlled entity onibel GmbH 442,772
Number of option rights 31.12.2009:
Option program: 2006: –; 2009: 250,000 |
| Chris Piggott Born: 1952
Education: M.A.
Position at Biotie: Chief Business Offi cer
Appointed as member of the Management Team: June 2009
Employment history: sanofi -aventis, VP Business Intelligence 2005–2007. Aventis, Senior Director, Business Development, 1998–2005. Hoechst Marion Roussel (UK), Head of Business Development & Strategic Marketing 1995–1998. Marion Merrell Dow (UK), Director of Marketing, 1991–1995. Merrell Dow (Switzerland), commercial positions including General Manager, MidEast/Africa, 1981–1991. Rhone Poulenc (UK), sales and marketing positions, 1974–1981. University of Cambridge, UK,M.A. in Pharmacology 1973
Key positions of trust: None
Number of shares held in Biotie 31.12.2009: –
Number of option rights 31.12.2009:
Option program: 2006: –; 2009: 250,000 |
 | Thomas Taapken
Born: 1965
Education: Ph.D.
Position at Biotie: Chief Financial Offi cer
Appointed as member of the Management Team: November 2008
Employment history: elbion NV, Chief Financial Offi cer 2005–2008. DVC Deutsche Venture Capital, Partner in life science investment team. sanofi -aventis, Managing Director of corporate VC fund 2002–2003; Head of venture capital group at sanofi -aventis and Director of business development at Burrill & Company (San Francisco, USA) 1998–2001; research manager, 1995–1998. University of Santa Barbara, USA, Postdoctoral fellow 1994–1995. Technical University of Berlin, Ph.D in chemistry 1994.
Key positions of trust: None
Number of shares held in Biotie 31.12.2009: 442,772
Number of option rights 31.12.2009:
Option program: 2006: –; 2009: 250,000 |
| ---
Updated April, 2010 |